Corey J. Langer, M.D.
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-5121
Fax: 215-615-5122
Lab: CP 215-806-6152
Fax: 215-615-5122
Lab: CP 215-806-6152
Education
B.A./M.D. (Liberal Arts and Medicine 6 year Combined)
Boston University, 1981.
Permanent linkB.A./M.D. (Liberal Arts and Medicine 6 year Combined)
Boston University, 1981.
Description of Research Expertise
Maturing role of immunotherapy in advanced NSCLC.Role of targeted agents in oncogene-driven NSCLC
New strategies in SCLC
Unique combined modality strategies integrating radiation and systemic treatment in LA-NSCLC and limited stage SCLC
Underserved populations, including older patients and those with compromised performance status.
Novel therapeutic venues in thoracic and head and neck cancer
Description of Clinical Expertise
Thoracic Medical Oncology with focus on NSCLC, SCLC, and MesotheliomaSelected Publications
Gerber DE, Wang Y, Langer CJ, Khullar OV, Kozono DE, Cornelius LA, Forde PM, Nwaneri MO, Neal JW, Talsania A, Leal TA, Patel M, Donthireddy KR, Waqar SN, Chaft JE, Govindan R, Sands JM, Malik S, Li T, Sun Z, Stinchcombe TE, Vokes EE, Mandrekar SJ, Oxnard GR, Carbone DP, Ramalingam SS.: Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial. Lancet Respir Med Aug 2026.Barsouk AA, Yaskolko M, Sussman JH, Sun L, Singh AP, Cohen RB, Aggarwal C, Marmarelis ME, Langer CJ.: Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC. Clin Lung Cancer 27: 50-55, Jul 2026.
Bleiberg BA, Scholes DG, Reed-Guy L, Dravid D, Sun LL, Singh AP, Cohen RB, Langer CJ, Marmarelis ME, Aggarwal C.: Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461] J Liq Biopsy 12: 100472, May 2026.
Bleiberg BA, Reed-Guy L, Cohen RB, Aggarwal C, Langer CJ, Singh AP, Marmarelis ME.: Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study. Front Oncol 16: 1795920, Apr 2026.
Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME.: Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC). Lung Cancer March 2026.
Bleiberg BA, Scholes DG, Reed-Guy L, Dravid D, Sun LL, Singh AP, Cohen RB, Langer CJ, Marmarelis ME, Aggarwal C.: The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing. J Liq Biopsy 12: 100461, Mar 2026.
Wang W, Scholes DG, Watts AC, Roy MA, Singhal S, Kucharczuk JC, Jarrar D, Predina J, Pechet TTV, Sun LL, Singh AP, Cohen RB, Langer CJ, Aggarwal C, Marmarelis ME.: EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer. JCO Precis Oncol 2026.
Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ.: Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy. Am J Clin Oncol Nov 2025.
Langer CJ, Harris J, Horwitz EM, Kies M, Ad VB, Wong SJ, Caudell JJ, Zeitzer KL, Spencer SA, Zhang Q, Yom SS, Le QT.: Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911. Int J Radiat Oncol Biol Phys 124: 50-60, Jul 2025.
Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S.: Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer Jun 2025.